Dealmaking Trends, Part II: The Valuation Divide
Late-stage products are more valuable than ever, as products and as licensing currency. Drug originators, for example, can generate the same kinds of partner funding and commitment from mere co-promotions that were once available only from joint ventures or outright exclusive out-licensing deals. But no one except Big Pharma seems to reap the rewards on Wall Street--largely because investors believe that new entrants can't overcome the increasing barriers to the drug business. With their shares in the doghouse, biotechs who have successfully launched products are struggling to craft strategies that will prove their staying power and long-term value.
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.